• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮腔内血管成形术治疗髂动脉、股动脉和腘动脉后的并发症。

Complications after percutaneous transluminal angioplasty in the iliac, femoral, and popliteal arteries.

作者信息

Weibull H, Bergqvist D, Jonsson K, Karlsson S, Takolander R

出版信息

J Vasc Surg. 1987 May;5(5):681-6.

PMID:2952811
Abstract

During a 5-year period percutaneous transluminal angioplasty (PTA) was attempted in 134 iliac, femoral, and popliteal arteries in 127 patients. Complications were systematically registered and classified as major, minor, and radiologic. Seventeen major complications (12.7%), including three deaths, occurred, as well as five minor (3.7%) and 13 radiologic complications (9.7%). The last group showed no clinical symptoms. The frequency of complications in our series is high compared with that found in a survey of 13 studies with 2043 patients. The most marked discrepancy was our high frequency of septic symptoms. A mortality rate of 2.2% was also higher in our series, but we have consequently registered the 30-day mortality rate to make comparisons with surgical series relevant. Radiologic alterations are usually not reported in other series probably because they are regarded as a part of the method, but we consider these alterations as potentially dangerous and important to report because they can result in clinically relevant complications. Because of the complications PTA should only be performed in centers in which complications can be optimally treated.

摘要

在5年期间,对127例患者的134条髂动脉、股动脉和腘动脉尝试进行经皮腔内血管成形术(PTA)。对并发症进行了系统登记,并分为严重、轻微和放射学并发症。发生了17例严重并发症(12.7%),包括3例死亡,以及5例轻微并发症(3.7%)和13例放射学并发症(9.7%)。最后一组无临床症状。与对2043例患者的13项研究的调查结果相比,我们系列中的并发症发生率较高。最明显的差异是我们的感染症状发生率较高。我们系列中的死亡率为2.2%也较高,但因此我们记录了30天死亡率,以便与手术系列进行相关比较。放射学改变在其他系列中通常未被报告,可能是因为它们被视为该方法的一部分,但我们认为这些改变具有潜在危险性且报告很重要,因为它们可导致临床相关并发症。由于存在并发症,PTA仅应在能够对并发症进行最佳治疗的中心进行。

相似文献

1
Complications after percutaneous transluminal angioplasty in the iliac, femoral, and popliteal arteries.经皮腔内血管成形术治疗髂动脉、股动脉和腘动脉后的并发症。
J Vasc Surg. 1987 May;5(5):681-6.
2
Percutaneous recanalization of total iliac and femoro-popliteal artery occlusions.
Eur J Radiol. 1987 May;7(2):91-3.
3
Transluminal angioplasty of the iliac, femoral, and popliteal arteries.髂动脉、股动脉和腘动脉的腔内血管成形术。
Radiology. 1979 Aug;132(2):285-8. doi: 10.1148/132.2.285.
4
Percutaneous transluminal angioplasty of the iliac arteries: 66 experiences.髂动脉经皮腔内血管成形术:66例经验
AJR Am J Roentgenol. 1980 Nov;135(5):937-44. doi: 10.2214/ajr.135.5.937.
5
Patency after iliac and femoro-popliteal angioplasty. Difference between angiographic and clinical results.
Acta Radiol. 1992 Jan;33(1):29-30.
6
Results of percutaneous transluminal angioplasty.
Radiology. 1983 Jan;146(1):57-60. doi: 10.1148/radiology.146.1.6217485.
7
[Percutaneous transluminal angioplasty in the treatment of arteriosclerosis of the lower extremities].经皮腔内血管成形术治疗下肢动脉硬化症
Tidsskr Nor Laegeforen. 1994 Nov 10;114(27):3195-8.
8
[Is percutaneous transluminal angioplasty of the femoral and popliteal arteries a justifiable procedure? A discussion in relation to 58 attempts].[股动脉和腘动脉经皮腔内血管成形术是一种合理的手术吗?关于58例尝试的讨论]
J Radiol. 1982 Aug-Sep;63(8-9):495-501.
9
Percutaneous transluminal angioplasty of occlusions of the femoral and popliteal arteries by subintimal dissection.经皮腔内血管成形术治疗股动脉和腘动脉闭塞:内膜下剥离术
Cardiovasc Intervent Radiol. 1990 Dec;13(6):357-63. doi: 10.1007/BF02578675.
10
[Percutaneous transluminal angioplasty].
AMB Rev Assoc Med Bras. 1982 Jul-Aug;28(7-8):173-7.

引用本文的文献

1
Long-term results of combined iliac balloon angioplasty and distal surgical revascularization.髂动脉球囊血管成形术与远端手术血管重建联合治疗的长期结果
Ann Surg. 1989 Sep;210(3):324-30; discussion 331. doi: 10.1097/00000658-198909000-00008.